NEW YORK (GenomeWeb) – Novigenix has signed a commercialization agreement with Dr Risch Medical Laboratory to distribute its PCR-based Colox blood test for early detection of colorectal cancer, giving the firm access to the Swiss German market and Lichtenstein.

The agreement comes after a similar one with Unilabs to target the French Swiss market and is part of the firm's overall European expansion plans.

To read the full story....

Register for Free.

Already have a GenomeWeb or 360Dx account?
Login Now.